Press release

Lund, Sweden, January 15, 2013

**Enzymatica: ColdZyme® Mouth Spray – for treating the common cold – to be introduced by the Swedish Apotek Hjärtat pharmacy chain**

**Enzymatica has concluded an agreement with Apotek Hjärtat, Sweden’s second largest pharmacy chain. During February 2013, Enzymatica’s medical device product, ColdZyme® Mouth Spray, will be introduced as part of the product range at Apotek Hjärtat.**

**“**The agreement signed with the Apotek Hjärtat pharmacy chain serves as further confirmation of the interest in our products. The Apotek Hjärtat pharmacy chain is Sweden’s second largest pharmacy group, with some 270 pharmacies nationwide,” notes Michael Edelborg Christensen, CEO at Enzymatica.

Enzymatica’s registered product, ColdZyme® Mouth Spray, will be on sale as part of the regular product range at Apotek Hjärtat, with its introduction as of February.

“The agreements concluded with two of the leading pharmacy chains – Apotek Hjärtat and Kronans Droghandel – mean that ColdZyme® Mouth Spray will be on sale throughout almost 50 percent of all pharmacies in Sweden. Negotiations with other pharmacy groups are proceeding according to plan,” adds Michael Edelborg Christensen.

**For more detailed information, contact:**

Michael Edelborg Christensen, CEO, Enzymatica AB (publ), 0768-14 41 66,

michael.christensen@enzymatica.se

**About ColdZyme® Mouth Spray**

ColdZyme® Mouth Spray is a medical device product, Class 1 (CE marked). The ColdZyme® Mouth Spray reduces the risk of contracting a cold and/or shortens the illness period at an early stage of the infection by creating a barrier of thin protecting film in the throat.

**About Enzymatica AB (publ)**

Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and registration of medical devices based on patented enzyme technology. Enzymatica utilizes marine enzyme, a cold-adapted trypsin derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. The ColdZyme® portfolio, which is currently available at health care stores, contains the predecessors to the products that are now registered as medical devices to treat the common cold, as well as dental/oral cavity disorders.

**About Enzymatica on the web**

[Enzymatica’s press room »](http://www.mynewsdesk.com/se/pressroom/enzymatica-ab)

[Enzymatica’s website »](http://www.enzymatica.se/index.php?id=1)

[Enzymatica on LinkedIn »](http://www.linkedin.com/company/1586902?trk=tyah)

[Enzymatica on Twitter »](https://twitter.com/Enzymatica_AB)

[For Investors »](http://www.aktietorget.se/QuotesInstrument.aspx?Language=1&InstrumentID=SE0003943620)

[ColdZyme website »](http://www.coldzyme.se/)

[ColdZyme on Facebook »](http://www.facebook.com/pages/ColdZyme/162799103808769)